PF PRISM CV FDA Approval NDA 021630

NDA 021630

PF PRISM CV

FDA Drug Application

Application #021630

Documents

Letter2003-12-24
Letter2004-04-29
Letter2004-12-29
Letter2005-03-29
Letter2006-03-22
Letter2006-12-28
Letter2010-06-24
Letter2010-06-24
Letter2011-11-21
Label2004-05-04
Label2005-03-29
Label2005-07-08
Label2006-01-05
Label2006-03-22
Label2008-02-14
Label2010-06-24
Label2010-06-24
Label2010-12-26
Label2011-11-21
Letter2005-07-15
Letter2006-01-19
Letter2008-02-07
Letter2006-05-22
Letter2008-03-13
Letter2010-06-24
Letter2008-06-03
Letter2010-06-24
Letter2010-12-21
Letter2010-11-30
Letter2011-06-02
Letter2014-04-08
Letter2015-02-05
Label2003-12-29
Label2004-12-29
Label2006-05-22
Label2006-12-04
Label2008-03-13
Label2010-06-24
Label2010-06-24
Label2010-11-21
Label2011-06-16
Label2014-04-08
Label2015-02-05
Review2006-07-25
Review2007-01-10
Review2012-11-09
Letter2017-06-16
Label2017-06-19
Label2017-07-31
Letter2017-08-02
Letter2018-10-11
Label2019-01-30
Letter2019-02-13
Label2019-04-30
Letter2019-05-02
Label2020-09-08
Letter2020-09-08
Letter2021-01-19
Label2021-01-26
Label2021-01-26
Letter2021-01-26
Label2021-04-19
Letter2021-04-19
Letter2021-10-14
Label2021-10-14
Letter2022-01-31
Label2022-02-01
Letter2022-08-17
Label2022-08-17
Letter2022-10-19
Label2022-10-21

Application Sponsors

NDA 021630PF PRISM CV

Marketing Status

Prescription001

Application Products

001FOR SUSPENSION;ORAL200MG/5ML1VFENDVORICONAZOLE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2003-12-19STANDARD
EFFICACY; EfficacySUPPL3AP2004-12-21STANDARD
LABELING; LabelingSUPPL4AP2005-03-24STANDARD
LABELING; LabelingSUPPL5AP2005-07-07STANDARD
LABELING; LabelingSUPPL6AP2005-12-18STANDARD
LABELING; LabelingSUPPL8AP2006-03-10STANDARD
LABELING; LabelingSUPPL9AP2008-02-05STANDARD
LABELING; LabelingSUPPL10AP2006-05-19STANDARD
LABELING; LabelingSUPPL11AP2006-12-01STANDARD
LABELING; LabelingSUPPL13AP2008-03-10STANDARD
LABELING; LabelingSUPPL14AP2010-06-17STANDARD
LABELING; LabelingSUPPL15AP2008-05-30STANDARD
LABELING; LabelingSUPPL18AP2010-06-17STANDARD
LABELING; LabelingSUPPL20AP2010-06-17UNKNOWN
LABELING; LabelingSUPPL21AP2010-06-17UNKNOWN
LABELING; LabelingSUPPL22AP2010-12-15UNKNOWN
LABELING; LabelingSUPPL23AP2010-11-21UNKNOWN
LABELING; LabelingSUPPL24AP2011-06-01UNKNOWN
LABELING; LabelingSUPPL26AP2011-11-16STANDARD
LABELING; LabelingSUPPL27AP2014-04-07STANDARD
LABELING; LabelingSUPPL28AP2015-02-03STANDARD
EFFICACY; EfficacySUPPL29AP2019-01-29PRIORITY
LABELING; LabelingSUPPL31AP2017-06-15STANDARD
LABELING; LabelingSUPPL32AP2017-07-28STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
LABELING; LabelingSUPPL33AP2018-10-04STANDARD
LABELING; LabelingSUPPL34AP2019-04-30STANDARD
LABELING; LabelingSUPPL36AP2021-01-14STANDARD
LABELING; LabelingSUPPL37AP2020-09-04STANDARD
LABELING; LabelingSUPPL38AP2021-01-25STANDARD
LABELING; LabelingSUPPL39AP2021-04-15STANDARD
LABELING; LabelingSUPPL40AP2021-10-13STANDARD
LABELING; LabelingSUPPL41AP2022-01-28STANDARD
LABELING; LabelingSUPPL42AP2022-10-18STANDARD
LABELING; LabelingSUPPL43AP2022-08-16STANDARD

Submissions Property Types

SUPPL1Null9
SUPPL14Null6
SUPPL18Null6
SUPPL20Null6
SUPPL21Null6
SUPPL22Null6
SUPPL23Null6
SUPPL24Null6
SUPPL26Null7
SUPPL27Null15
SUPPL28Null6
SUPPL29Null6
SUPPL31Null6
SUPPL32Null6
SUPPL33Null7
SUPPL34Null7
SUPPL36Null7
SUPPL37Null6
SUPPL38Null6
SUPPL39Null6
SUPPL40Null6
SUPPL41Null7
SUPPL42Null7
SUPPL43Null6

TE Codes

001PrescriptionAB

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21630
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.